Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Charles River Laboratories(CRL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CRL
11/06/2026: CRL (5-star) is a STRONG-BUY. BUY for 106 days. Simulated Profits (77.78%). Updated daily EoD!
Charles River Laboratories is a major global provider of research and development support for the pharmaceutical and biotechnology industries. The company is best known for its integrated platform that spans from early drug discovery to specialized manufacturing support. Its primary growth story centers on the secular trend of outsourcing R&D, coupled with expansion into high-growth areas like cell and gene therapy. However, the business faces significant risks from cyclical downturns in biotech funding and high operational complexity. It is primarily suited for long-term growth-oriented investors, though it is currently navigating a challenging environment that requires careful monitoring of sector spending and margin management.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers exposure to the growing R&D outsourcing trend but is currently hampered by cyclical weakness in biotech funding. |
| Momentum investor | Weak fit | The stock has faced headwinds in recent periods, making it less attractive for momentum-based strategies without a clear upturn signal. |
| Value investor | Mixed fit | Valuation has compressed due to market concerns, potentially offering entry for patient investors if fundamentals stabilize. |
| Dividend investor | Weak fit | The company does not pay a cash dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | Exposure to biotech sector volatility and high acquisition-related integration risk creates a profile unsuitable for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | The stock is highly sensitive to biotechnology sector sentiment and R&D budget cycles. |
| Valuation risk | Medium | Current valuations are dependent on a recovery in client research spending and margin improvement. |
| Competition risk (CRO consolidation) | Medium / high | Intense competition from well-capitalized peers and potential pricing pressure impact long-term margin stability. |
| Business quality | Strong | The company provides essential, non-discretionary services within the drug development pipeline. |
| Dividend income | Low / none | Investors receive no direct income from the company's capital allocation policy. |
| Execution risk | Medium | Maintaining operational quality across a diverse global network requires consistent, high-level management execution. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit 34.64% | Avg. Invested days 35 | Today’s Advisory Regular Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 11/06/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 16.17B USD | Price to earnings Ratio 366.87 | 1Y Target Price 333.53 |
Price to earnings Ratio 366.87 | 1Y Target Price 333.53 | ||
Volume (30-day avg) 1.2M shares | Beta 1.34 | 52 Weeks Range 146.20 - 379.63 | Updated Date 11/08/2026 |
52 Weeks Range 146.20 - 379.63 | Updated Date 11/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.92 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Research Models | Supply of laboratory animal models and biological products. | The foundational part of the business, providing essential inputs for early-stage research. |
| Discovery and Safety Assessment | Toxicology and drug discovery services for pre-clinical development. | The primary revenue driver, helping drug makers prove the safety of new medicines. |
| Manufacturing Support | Quality control and microbial testing for pharmaceutical production. | Provides stable, recurring revenue from long-term manufacturing contracts. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 2.98 | Actual 3.09 |
Profitability
Profit Margin 1.01% | Operating Margin (TTM) 23.42% |
Management Effectiveness
Return on Assets (TTM) 4.74% | Return on Equity (TTM) 1.27% |
Valuation
Trailing PE 366.87 | Forward PE 27.32 | Enterprise Value 18.82B | Price to Sales(TTM) 4.07 |
Enterprise Value 18.82B | Price to Sales(TTM) 4.07 | ||
Enterprise Value to Revenue 4.73 | Enterprise Value to EBITDA 63.99 | Shares Outstanding 47.92M | Shares Floating 47.40M |
Shares Outstanding 47.92M | Shares Floating 47.40M | ||
Percent Insiders 0.47 | Percent Institutions 115.43 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.